The High Resolution MASS spectrometry in Personalised Medicine: Retinol-Binding Protein 4 as a Candidate Biomarker Predictor of Progression in Bladder Urothelial Carcinoma

Mariana Medeiros; José Luis Capelo-Martínez; Hugo Miguel  Baptista Carreira dos Santos; Luís André  Botelho de Carvalho; Luís Campos Pinheiro

doi:10.24915/aup.156

Authors

Mariana Medeiros Centro de Responsabilidade Integrada de Urologia /CRI Urologia do Centro Hospitalar e Universitário de Lisboa Central, Portugal
José Luis Capelo-Martínez Departamento de Química, Faculdade de Ciências e Tecnologias, Caparica, Portugal
Hugo Miguel Baptista Carreira dos Santos Departamento de Química, Faculdade de Ciências e Tecnologias, Caparica, Portugal
Luís André Botelho de Carvalho Departamento de Química, Faculdade de Ciências e Tecnologias, Caparica, Portugal
Luís Campos Pinheiro Centro de Responsabilidade Integrada de Urologia /CRI Urologia do Centro Hospitalar e Universitário de Lisboa Central, Lisboa, Portugal

DOI:

https://doi.org/10.24915/aup.156

Keywords:

Biomarkers, Tumor, Retinol-Binding Proteins, Plasma, Urinary Bladder Neoplasms

Abstract

Introduction: Bladder cancer (BC) is the seventh most commonly diagnosed cancer in males. A large proportion of T1 cases and some Ta cases are under-staged and the significant risk of residual tumour after initial TURB of TaT1 lesions has been demonstrated. A second TURB is recommended in T1 tumours because it can increase recurrence-free survival (RFS) providing prognostic information. Non-invasive methods differentiating bladder cancer stages would be essential for diagnosis of under staged cases. Previously we demonstrated that a panel of urinary proteins measured by high resolution mass spectrometry could predict bladder cancer stages namely Ta, T1 and T2 cases. Our aim is to increase the accuracy of the biomarker panel for BC stage differentiation using a more patients, also intending to identify proteins that could be a signature to bladder cancer progression.
Methods: Forty-eight urine samples were collected from volun- teers of these groups: 20 patients with bladder cancer stage Ta; 19 patients with BC stage T1 and 9 patients with BC stage T2+ (T2, T3 and T4). Urinary proteome was cleaned and digested using the Filter-Aided Sample Preparation methodology and analysed by liquid chromatography-mass spectrometry. For protein identification and label-free quantification we used MaxQuant, the data was further interrogated with the bioinformatics platform Perseus.
Results: A biomarker panel was developed which consists of 87 proteins which were down-regulated between three different urothelial bladder carcinoma stages evaluated. Retinol-binding protein 4 (RBP4) consistently increases from Ta to T1, to T2+ (p <0.001) and in high grade tumours (p = 0.006).
Conclusion: Our results showed a proteomic biomarker panel capable to differentiate bladder cancer stages. Besides, retinolbinding protein 4 can be a candidate signature of progression.

Downloads

Download data is not yet available.

References

Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41:523-31. doi: 10.1016/s0302-2838(02)00068-4.

Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170: 433-7. doi: 10.1097/01.ju.0000070437.14275.e0.

Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175:1641-4. doi: 10. 1016/S0022-5347(05)01002-5.Ê

Rosário Fernandes FJ, Flores J, Horvatovich P, Lodeiro C, Martinez JL, Santos H, et al. New biomarkers of bladder cancer in liquid biopsies. Eur Urol Suppl.2019;18: e1638-9. doi: 10.1016/s1569-9056 (19)31190-x

International Agency for research on Cancer. Cancer Incidence in Five Continents. [accessed Jan 2021] Available at: https://ci5.iarc.fr/

European Association of Urology. Guidelines of European Association of Urology 2020. [accessed Jan 2021] Available at: http://uroweb.org/guidelines/compilations-of-all-guidelines/

Naselli A, Hurle R, Paparella S, Buffi NM, Lughezzani G, Lista G, et al. Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2018;4:558-67. doi: 10.1016/j.euf.2016.12.011.

Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, et al. Proteome-based classification of Nonmuscle Invasive Bladder Cancer. Int J Cancer. 2020;146:281-94. doi: 10. 1002/ijc.32556.

UniProt consortium. UniProt. [accessed Jan 2021] Available at: https://www.uniprot.org/

Frantzi M, Latosinska A, Belczacka I, Mischak H. Urinary proteomic biomarkers in oncology: ready for implementation? Expert Rev Proteomics. 2019;16:49-63. doi: 10.1080/14789450.2018.1547193.

Bryan RT, Regan HL, Pirrie SJ, Devall AJ, Cheng KK, Zeegers MP, et al. Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. Br J Cancer. 2015;112: 1052-8. doi: 10.1038/bjc.2015.21.Ê

Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, et al. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017;8:722-41. doi: 10.18632/oncotarget.13546.

Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28:4531-8. doi: 10.1200/JCO.2009.27.2146.

Lanzetti L, Di Fiore PP. Behind the Scenes: Endo/Exocytosis in the Acquisition of Metastatic Traits. Cancer Res. 2017;77:1813-7. doi: 10.1158/0008-5472.CAN-16-3403.

Zabetian-Targhi F, Mahmoudi MJ, Rezaei N, Mahmoudi M. Retinol binding protein 4 in relation to diet, inflammation, immunity, and cardiovascular diseases. Adv Nutr. 2015;6:748-62. doi: 10.3945/an. 115.008292.

Abola MV, Thompson CL, Chen Z, Chak A, Berger NA, Kirwan JP, et al. Serum levels of retinol-binding protein 4 and risk of colon adenoma. Endocr Relat Cancer. 2015;22:L1-4. doi: 10.1530/ERC-14-0429.

Berry DC, Noy N. Retinol Binding Protein 4: Role in Diabetes and Cancer. In: ReizesO, Berger NA, editors. Adipocytokines, Energy Balance, and Cancer. Cham: Springer; 2017. p. 89–107.